



Document Purpose

Data was analysed across 10 GP practices within the Cheshire Merseyside STP to establish baseline level data on lipid management in the context of key indications for treatment with statin therapy

Method of data collection

Authorisation was gained from individual GP practices to run a set of queries on the GP clinical system designed to interrogate and extract data relevant to lipid management for a defined group of patients meeting agreed inclusion criteria

Date period for data collection

Data was collected between June 2018 and July 2018

Definition of clinical inclusion criteria

Patients were included within the data set if they matched any of the following criteria:

- A recorded diagnosis of any of the following conditions: atherothrombotic cardiovascular disease (A-T CVD) comprising: ischaemic heart disease (IHD), myocardial infarction (MI), stroke (CVA) or transient ischaemic attack (TIA) or peripheral arterial disease (PAD), type II
- Diabetes, chronic kidney disease (CKD) or familial hypercholesterolaemia (FH)
- 2 A recorded QRISK2 score > 10%
- 3 Currently receiving therapy with a statin treatment

Assumptions and limitations

Using the dataset calculations to determine % reduction in non-HDL cholesterol (non-HDL C) levels using the following assumptions:

1 The highest recorded total cholesterol (TC) and/or low density lipoprotein (LDL) reading recorded in an individuals note is assumed to be the **baseline** value i.e. untreated level

2 The most recent TC/LDL/HDL value recorded in an individuals notes is taken as the **latest** value, reflecting any reduction resulting from lipid modification therapy

3 Where a patients is taking a current statin, the difference in baseline to latest value is assumed to be an effect of that statin therapy rather than any other statin therapy taken between baseline and latest values

Limitations exist when using the above method to calculate treatment effect including:

1 The baseline may not be a true baseline figure as the patient may have been on a statin when the measurement was taken

2 The non-HDL C calculation uses the same HDL value for both baseline and current non-HDLC values as we do not have a HDL value at the same point in time as the 'highest' TC/LDL reading

Summary detail of 10 practices included within the database including population, patients identified, IHD prevalence and statin treatment/exception rates within IHD and index of multiple deprivation 2015 (IMD) score

		IMD Score*	Patients with QRISK recorded (%)†	nationts with IHD	Patients with IHD	IHD Prevalence (%)	Number of patients identified	Practice postcode categorisation	List Size	Practice Name
score	Key to IMD	11	38%	18%	76%	3.30%	2,126	Urban City and Town Area	9,900	Practice 1
least depri	≤ 8.49	14	74%	13%	78%	4.00%	3,784	Urban City And Town area	13,400	Practice 2
	<u> 8.5 - 13.79</u>	50	96%	4%	87%	4.04%	1,082	Urban Major Conurbation area	4,300	Practice 3
	13.8 - 21.35	58	96%	1%	88%	3.87%	2,445	Urban Major Conurbation area	9,200	Practice 4
↓ ↓	21.36 - 34.17	37	95%	0%	85%	2.96%	609	Urban Major Conurbation area	2,500	Practice 5
most depri	≥34.18	41	97%	3%	86%	3.62%	2,463	Urban Major Conurbation area	10,700	Practice 6
eu.ox.ac.uk/ir	https://tools.npe	11	64%	13%	74%	4.66%	2,754	Urban City and Town Area	9,600	Practice 7
		20	75%	4%	90%	3.53%	2,706	Urban City and Town Area	12,200	Practice 8
		11	69%	11%	79%	4.05%	4,522	Urban Major Conurbation area	16,600	Practice 9
		42	37%	4%	80%	3.49%	1,585	Urban Major Conurbation area	7,800	Practice 10

*IMD score rounded to nearest whole number


Programme stakeholders: HEALTH & CARE PARTNERSHIP FOR CHESHIRE & MERSEYSIDE, NORTH WEST COAST STRATEGIC CLINICAL NETWORK,


NORTH WEST COAST ACADEMIC HEALTH CARE NETWORK INNOVATION AGENCY, AMGEN LIMITED and SALVERA SERVICES






Executive Summary:











Latest average lipid levels across all patients identified within sample dataset

Average last TC readings	Atorvastatin 80mg	High intensity	Medium intensity	Low intensity	No Statin
A-T CVD	4.0	4.2	4.1	4.5	5.1
MI	3.9	4.0	4.0	4.3	5.0
Primary prevention	5.0	4.8	4.5	4.8	5.6
Coded FH	5.8	6.0	5.4	5.3	7.0

Average last LDL reading	Atorvastatin		Medium		
	80mg	High intensity	intensity	Low intensity	No Statin
A-T CVD	2.3	2.3	2.1	2.4	2.9
MI	2.3	2.2	2.0	2.3	2.9
Primary prevention	2.8	2.8	2.4	2.7	3.4
Coded FH	4.1	3.8	3.6	2.8	4.8

Average last non-HDL C	Atorvastatin		Medium		
	80mg	High intensity	intensity	Low intensity	No Statin
A-T CVD	2.8	2.9	2.7	3.1	3.7
МІ	2.7	2.8	2.7	3.0	3.7
Primary prevention	3.7	3.4	3.1	3.4	4.1
Coded FH	4.4	4.5	3.9	3.9	5.6

Number of discreet comorbidities (IHD, MI, DM, CKD, STROKE/TIA, PAD, TC≥7.5, Diagnosis of FH)

3

64

4

5

6

Definition of statin potencies used in dashboard report (NICE CG181 Appendix A: Grouping of statins)

	Reduction in low-density lipoprotein cholesterol					
Dose (mg/day)	5	10	20	40	80	
Fluvastatin	-	-	21% ¹	27% ¹	33% ²	
Pravastatin	-	20% ¹	24% ¹	29% ¹	-	
Simvastatin	-	27% ¹	32% ²	37% ²	42% ^{3,4}	
Atorvastatin	-	37% ²	43% ³	49% ³	55% ³	
Rosuvastatin	38% ²	43% ³	48% ³	53% ³	-	

¹ 20%-30%: low intensity.

² 31%-40%: medium intensity.

³ Above 40%: high intensity.

⁴ Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80 mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks.



>40% reduction non-HDLC

<40% reduction non-HDLC</p>



